Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
EUROPEAN regulators are following in the footsteps of the US Food and Drug Administration (FDA) with plans to help pharmaceutical companies win approval for novel Alzheimer's drugs that treat the earliest stages of the memory-robbing disease.
The European Medicines Agency